In Cephalon, Teva Will Get An Expanded Innovative R&D And Branded Portfolio
This article was originally published in The Pink Sheet Daily
Executive SummaryThe giant Israeli generics firm extols Cephalon's R&D but the deal's real value may be more nuanced: a combination of cost synergies, late-stage pipeline assets, and expansion of Teva's mix of branded products in anticipation of upcoming challenges in both the branded and generics businesses.
You may also be interested in...
Now studying stem-cell candidate MPC-150-IM in two 600-patient Phase III trials in advanced heart failure, the partners could complete the Phase III program more quickly and less expensively.
Teva’s new management has homed in on pain and respiratory disease as two core therapeutic areas. During the firm’s second quarter earnings call, CEO Erez Vigodman gave a sneak peek at his comprehensive portfolio review.
Several antibody drugs are in late-stage development to treat severe asthma and could reach the market in the next two years. But competition for niche subsets of patients will be fierce, and tailoring the right medications to the right patients to justify the higher cost of treatment will require advances in biomarker development.